Biotechnology
Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cell carcinoma (ccRCC): * Primary endpoint met: Sensitivi...
2023-02-20 07:10
2410
Terumo Blood and Cell Technologies' IMUGARD Platelet Pooling Set Cleared by FDA
IMUGARD to Help Strained U.S. Platelet Supply Meet Growing Need LAKEWOOD, Colo., Feb. 16, 2023 /PRNewswire/ -- Today, Terumo Blood and Cell Technologies announces U.S. Food and Drug Administration (FDA) clearance and official launch of its IMUGARD® WB Platelet Pooling Set, which supports extende...
2023-02-17 03:48
2012
GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
* Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe forNew Zealand patients * YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 16, 2023 /PRNewswire/ -- Independen...
2023-02-17 03:00
2333
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in PD-1-Enhanced DNA vaccines and immunotherapies,announced the ...
2023-02-16 20:36
5097
Alibaba Entrepreneurs Fund Launches JUMPSTARTER 2023 Global Pitch Competition
Newly added HKD1 million cash prize and a maximum total investment of up to USD5 million Encourage start-ups to integrate UN Sustainable Goals into businesses HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Alibaba Hong Kong Entrepreneurs Fund ("AEF") today announced the JUMPSTARTER 2023 Global Pitch C...
2023-02-16 18:23
3183
Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B
HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the Liver ("APASL Annual Meeting 2023") demonstrates that ASC22 (Envafol...
2023-02-16 17:10
3115
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committ...
2023-02-16 14:00
2714
GNOMIX: An Australian Case Study to Democratise Clinical Applications of Genomics with MGI's DNBSEQ™ Platforms
BRISBANE, Australia, Feb. 16, 2023 /PRNewswire/ -- GNOMIX
2023-02-16 12:00
2685
Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial
YANTAI, China, Feb. 16, 2023 /PRNewswire/ -- Luye Pharma Group today announced that BA2101, an investigational anti-IL-4Rα antibody developed by its subsidiary Boan Biotech, has been administered for the first patient in a Phase I clinical trial. Recognized as a Class 1 innovative biological prod...
2023-02-16 08:15
3504
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
ROCKVILLE, Md. and SUZHOU, China, Feb. 16, 2023 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology ...
2023-02-16 08:00
3515
WuXi AppTec Named "Industry Mover" in S&P Global Sustainability Yearbook 2023
SHANGHAI, Feb. 15, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced today that it ...
2023-02-16 08:00
2001
Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery
Collaboration to develop 3D in vitro models of the brain for the discovery of
therapeutic candidates using Inventia's novel 3D cell culture platform, RASTRUM™
SYDNEY, Feb. 15, 2023 /PRNewswire/ -- February 16, 2023, Inventia Life Science
2023-02-16 06:00
2493
Tetracore Announces USDA Purchase of ASF and FMD Diagnostic Test Kits
ROCKVILLE, Md., Feb. 16, 2023 /PRNewswire/ -- Tetracore, Inc. (Tetracore®) is pleased to announce its partnership with the United States Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) to provide a stock of PCR kits for both African Swine Fever (ASF) and Foo...
2023-02-16 04:35
3157
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Randomized, double-blind, placebo-controlled study to evaluate efficacy of novel pan-GI prokinetic in patients with gastroparesis ROSCREA, Ireland and FREIBURG, Germany, Feb. 15, 2023 /PRNewswire/ -- Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovativ...
2023-02-15 21:30
2987
AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider
NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platfo...
2023-02-15 21:00
3418
Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
* The first Chinese biosimilar approved in both China and the EU, and potentially to be approved in the U.S. - * HLX02 (trastuzumab for injection, trade name in China: HANQUYOU; trade name inEurope: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®) has been approved in more than 3...
2023-02-15 16:49
3060
GILEAD TO PRESENT DATA AT APASL 2023 ON EFFECTIVE MODELS FOR MONITORING AND TREATING HEPATITIS C AND EFFICACY OF ANTIVIRAL TREATMENTS FOR HIV-1 AND HBV-COINFECTED ADULTS
- Study recommends a simplified strategy for baseline testing and minimal monitoring for treatment of hepatitis C virus (HCV) infection with DAA Therapies - Review of implementation science projects toward HCV Elimination by 2030 in Asia proved effective in improving patient outcomes - Efficacy ...
2023-02-15 10:00
2645
Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy
ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-02-15 08:00
3898
Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced inFebrua...
2023-02-15 04:51
2027
Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)
Initial Part A results to be presented at the upcoming American Society of Cataract and Refractive Surgery Annual Meeting EB-301 has the potential to be the world's first approved rhCIII biosynthetic corneal implant for the treatment of corneal blindness SUZHOU, China and SAN FRANCISCO, Feb. 14,...
2023-02-15 01:00
1890
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 301 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
11004
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
7041
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
6966
